Immunohistochemical analysis of heat shock proteins in triple negative breast cancer: HSP60 expression is a marker of poor prognosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F18%3A43914525" target="_blank" >RIV/62156489:43210/18:43914525 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.irog.net/archives" target="_blank" >http://www.irog.net/archives</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.12892/ejgo4347.2018" target="_blank" >10.12892/ejgo4347.2018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immunohistochemical analysis of heat shock proteins in triple negative breast cancer: HSP60 expression is a marker of poor prognosis

Popis výsledku v původním jazyce

Triple negative breast cancer (TNBC) is an aggressive and rapidly growing subtype of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression, rendering it resistant to targeted therapies. In the absence of molecular targets, the pathogenesis of TNBC is not well understood and many studies are focused towards identifying the pathways and molecular signatures associated with the initiation and progression of TNBC. Heat shock proteins emerged as key players in the tumorigenic pathways of several types of cancer including TNBC. In the present study, paraffin-embedded tumor tissues of 66 Jordanian TNBC patients were analyzed, retrospectively. by immunohistochemistry to investigate the expression of HSP90, HSP70, HSP60, and HSP27 in Jordanian TNBC patients. The expression of the aforementioned markers was also examined using disease-free survival (DFS) along with a variety of clinical and pathological characteristics such as age, stage/grade of tumor, and nodal involvement. Positive expression of HSP90, HSP60, HSP27, and HSP70 was shown in 89%. 79%, 76%, and 40% of the cases analyzed, respectively. HSP60 positive expression was found to be significantly correlated with advanced stage (pT3/pT4) of the tumor (p 0.05), nodal involvement (p = 0.03), and older age of patients (p = 0.03). Among the clinical and pathological variables analyzed in the present study, it was found that advanced stage (pT3/pT4) of the tumor and older age of the patients were significantly associated with worse DFS (p = 0.001 and 0.02, respectively). Additionally, positive expression of HSP60 showed to be correlated with worse DFS (p = 0.05). This study highlights the importance of HSP60 as a marker of poor prognosis in TNBC patients.

Název v anglickém jazyce

Immunohistochemical analysis of heat shock proteins in triple negative breast cancer: HSP60 expression is a marker of poor prognosis

Popis výsledku anglicky

Triple negative breast cancer (TNBC) is an aggressive and rapidly growing subtype of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression, rendering it resistant to targeted therapies. In the absence of molecular targets, the pathogenesis of TNBC is not well understood and many studies are focused towards identifying the pathways and molecular signatures associated with the initiation and progression of TNBC. Heat shock proteins emerged as key players in the tumorigenic pathways of several types of cancer including TNBC. In the present study, paraffin-embedded tumor tissues of 66 Jordanian TNBC patients were analyzed, retrospectively. by immunohistochemistry to investigate the expression of HSP90, HSP70, HSP60, and HSP27 in Jordanian TNBC patients. The expression of the aforementioned markers was also examined using disease-free survival (DFS) along with a variety of clinical and pathological characteristics such as age, stage/grade of tumor, and nodal involvement. Positive expression of HSP90, HSP60, HSP27, and HSP70 was shown in 89%. 79%, 76%, and 40% of the cases analyzed, respectively. HSP60 positive expression was found to be significantly correlated with advanced stage (pT3/pT4) of the tumor (p 0.05), nodal involvement (p = 0.03), and older age of patients (p = 0.03). Among the clinical and pathological variables analyzed in the present study, it was found that advanced stage (pT3/pT4) of the tumor and older age of the patients were significantly associated with worse DFS (p = 0.001 and 0.02, respectively). Additionally, positive expression of HSP60 showed to be correlated with worse DFS (p = 0.05). This study highlights the importance of HSP60 as a marker of poor prognosis in TNBC patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Gynaecological Oncology

ISSN

0392-2936

e-ISSN

—

Svazek periodika

39

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

9

Strana od-do

926-934

Kód UT WoS článku

000452166200014

EID výsledku v databázi Scopus

2-s2.0-85058863737